Clinical trials: Neuroendocrine Tumors
Heathy Volunteer, Parkinsonian Syndromes
Ultralow Dose PET Imaging of 18F-FDOPA
The goal of this clinical trial is to evaluate an investigational ultralow dose PET imaging technique for Parkinsonian syndromes, neuroendocrine tumors, and gliomas detection and monitoring.
- Conditions
- Heathy Volunteer, Parkinsonian Syndromes, Neuroendocrine (NE) Tumors, Gliomas
- Trial name
- NCT07542158
- Testing
- 18F-FDOPA
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Akiva Mintz
Pancreatic Ductal Adenocarcinoma, Pancreatic Diseases
Pancreatic Cancer Screening Through the Detection of Elastase-1 Combined With Other Examinations
This is a prospective cohort study. The investigators enroll subjects with pancreatic ductal adenocarcinoma (PDAC), individuals at high risk for PDAC, patients with other pancreatic diseases, patients with CA19-9 elevation and…
- Conditions
- Pancreatic Ductal Adenocarcinoma, Pancreatic Diseases, Pancreatic Elastase 1, Pancreatic Neuroendocrine Tumor
- Trial name
- NCT06041009
- Testing
- Pancreatic elastase-1 in blood serum
- Where
- China
- Volunteers
- 2,100 people, healthy volunteers welcome
- Sponsor
- Qilu Hospital of Shandong University
Malignant Melanoma
Suction Drain in Axillary Lymph Node Dissection for Malignant Melanoma
Postoperative complications like seroma formation and wound site infection readily occur following completion axillary lymph node dissection (ALND) for malignant melanoma.
- Trial name
- NCT04648163
- Where
- Austria
- Volunteers
- 118 people
- Sponsor
- Medical University of Graz
Stage IV Melanoma
A-dmDT390-bisFv(UCHT1) Fusion Protein With Ionizing Radiation and Pembrolizumab for the Treatment of Stage IV Melanoma
This study evaluates the effectiveness of adding a single four-day treatment of the fusion protein A-dmDT390-bisFv(UCHT1) - plus single palliative tumor radiation - with standard of care KEYTRUDA (Pembrolizumab) therapy for the…
- Trial name
- NCT02990416
- Testing
- A-dmDT390-bisFv(UCHT1), Pembrolizumab, Ionizing Radiation
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- Virogen Biotechnology Inc.
Melanoma, Cancer Survivorship
Mentored Community Gardening for Individuals With Skin Cancer
The investigators will conduct a single-arm pilot feasibility trial of mentored community gardening for melanoma survivors integrating dosimeters and accelerometers.
- Conditions
- Melanoma, Cancer Survivorship, Skin Cancer, Basal Cell Carcinoma
- Trial name
- H4H2-AZ (NCT05648604)
- Testing
- Mentored Community Gardening
- Where
- United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- University of Arizona
Melanoma
The Prognostic Value of 18F-PFPN PET Imaging in Patients With Malignant Melanoma
This is a monocentric prospective study. This study aims to investigate the prognostic value of the novel melanin-targeted imaging modality 18F-PFPN PET in patients with melanoma and seek independent prognostic factors for…
- Trial name
- NCT05645484
- Testing
- 18F-PFPN, 18F-FDG
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Advanced Solid Tumor
A Phase I Study of HS-20108 in Participants With Advanced Solid Tumors
This is a Phase I clinical study of HS-20108. The purpose of this study is to evaluate the safety, tolerability, PK and efficacy of intravenous HS-20108 in patients with advanced solid tumors.
- Trial name
- NCT06936735
- Testing
- HS-20108 Monotherapy
- Where
- China
- Volunteers
- 502 people
- Sponsor
- Hansoh BioMedical R&D Company
Melanoma, Cancer
Study of a Multi-Antigen Therapeutic Vaccine in Patients With Metastatic Melanoma
Primary objective: To evaluate the clinical activity of the vaccine regimen, as indicated by progression-free survival versus the clinical activity of the reference treatment.
- Trial name
- NCT00613509
- Testing
- ALVAC(2) Melanoma multi-antigen therapeutic vaccine, Intron A, Interferon alpha -2b
- Where
- 19 sites in United States, Canada
- Volunteers
- 23 people
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Solid Tumor
Neo-T in Treating Patients With Advanced Solid Tumors(GI-NeoT-03)
The primary objective of this study is to evaluate the safety of Neo-T in combination with anti-PD1 in patients with solid tumors.
- Trial name
- NCT05798533
- Testing
- Neo-T, Toripalimab, Tislelizumab
- Where
- 2 sites in China
- Volunteers
- 6 people
- Sponsor
- BGI, China
Neurofibromatosis 2, Vestibular Schwannoma
Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors
In this research study the researchers want to learn more about the effects (both good and bad) the study drug selumetinib has on participants with neurofibromatosis type II (NF2) related tumor.
- Conditions
- Neurofibromatosis 2, Vestibular Schwannoma, Meningioma, Ependymoma
- Trial name
- SEL-TH-1601 (NCT03095248)
- Testing
- Selumetinib
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Melanoma, Non-melanoma Skin Cancer
DERM Health Economics Study
This study aims to provide an initial assessment of the potential impact DERM could have on the number of onward referrals for a face to face dermatologist review and/or biopsy from a teledermatology-based service, and to improve…
- Trial name
- NCT04123678
- Testing
- Deep Ensemble for the Recognition of Malignancy (DERM)
- Where
- United Kingdom
- Volunteers
- 700 people
- Sponsor
- Skin Analytics Limited
Cutaneous Tumor, Optical Coherence Tomography
Ex-vivo Examination of Excisions of Skin Tumors by Confocal Optical Coherence Tomography (LC-OCT) With Integrated Dermoscopy and Comparison With Histology (DERMOCTAV)
This project aims to validate ex vivo the use of the OCTAV® prototype integrating the "dermoscope" function before an in vivo application, by comparing images obtained by the OCTAV® prototype integrating the "dermoscope" function…
- Conditions
- Cutaneous Tumor, Optical Coherence Tomography, Basal Cell Carcinoma, Squamous Cell Carcinoma
- Trial name
- DERMOCTAV (NCT05340543)
- Testing
- Confocal optical coherence tomography - OCTAVE
- Where
- France
- Volunteers
- 150 people
- Sponsor
- GCS Ramsay Santé pour l'Enseignement et la Recherche
Prostate Adenocarcinoma With Focal Neuroendocrine Differentiation, Prostate Cancer
RET-Targeted Molecular Imaging Probes in Prostate Cancer
The goal of this observational diagnostic imaging study is to evaluate the value of RET-targeted PET/CT molecular imaging in diagnosing neuroendocrine prostate cancer (NEPC) and in assessing disease activity, treatment response…
- Trial name
- NCT07886138
- Testing
- RET-targeted PET/CT molecular imaging, PSMA-targeted PET/CT imaging
- Where
- China
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Xiangya Hospital of Central South University
Choroidal Melanoma
Ranibizumab as Adjuvant Therapy for the Treatment of Choroidal Melanoma (Cohort 2)
Ranibizumab has proven to be of benefit to improve the perfusion in the retina of patients with Choroidal Melanoma. The investigators consider that higher doses of Ranibizumab can help reduce the number of laser treatments that…
- Trial name
- NCT01251978
- Testing
- Ranibizumab 2 mg, 0.5 mg Ranibizumab
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- New England Retina Associates
Neuroendocrine Tumors, Liver Metastases
A Multicenter Study Evaluating Efficacy and Safety of 177Lu-DOTA-TATE Based on Kidney-Dosimetry in Patients With Disseminated Neuroendocrine Tumors
By improved kidney dosimetry including biological effective dose and taking into account potential risk factors (especially for kidney toxicity), it might be possible to give an optimal and personalized treatment with…
- Trial name
- ILUMINET (NCT01456078)
- Testing
- 177Lu-DOTA-TATE
- Where
- 2 sites in Sweden
- Volunteers
- 60 people
- Sponsor
- Lund University Hospital
Melanoma Stage III, Melanoma Stage IV
A Study of Combination with TBI-1401(HF10) and Ipilimumab in Japanese Patients with Unresectable or Metastatic Melanoma
The purpose of this study is to determine if TBI-1401(HF10) in combination with ipilimumab is effective in Japanese patients with stages IIIB, IIIC, or IV unresectable or metastatic melanoma.
- Trial name
- NCT03153085
- Testing
- TBI-1401(HF10), Ipilimumab
- Where
- 12 sites in Japan
- Volunteers
- 28 people
- Sponsor
- Takara Bio Inc.
Neuroendocrine Tumors, Carcinoma, Neuroendocrine
Natural History Study of Children and Adults With Neuroendocrine Neoplasms (NEN)s
Background: Neuroendocrine neoplasms (NENs) are rare tumors that originate in neuroendocrine cells. NENs can affect almost any part of the body. People with low-grade tumors can live many years.
- Trial name
- NCT04488263
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Melanoma, Breast Cancer
Coxsackie Virus A21 Administered Intravenously (IV) for Solid Tumour Cancers (PSX-X04)
Coxsackie A21 (CVA21) virus is to be administered by IV infusion to patients with Stage 4 melanoma, prostate and breast cancer. This is a dose escalation, safety study.
- Conditions
- Melanoma, Breast Cancer, Prostate Cancer
- Trial name
- PSX-X04 (NCT00636558)
- Testing
- CVA21
- Where
- 2 sites in Australia
- Volunteers
- 8 people
- Sponsor
- Viralytics
Paraganglioma/ Phaeochromocytoma, Melanoma and Other Malignant Neoplasms of Skin
An International Study on Pediatric Patients With Rare Tumors.
The PARTNER study is an international, prospective, observational study of paediatric patients with very rare tumours.
- Conditions
- Paraganglioma/ Phaeochromocytoma, Melanoma and Other Malignant Neoplasms of Skin, Gastrointestinal Stromal Tumor (GIST), Adrenocortical Tumor
- Trial name
- PARTNER (NCT07072143)
- Where
- Italy
- Volunteers
- 6,250 people
- Sponsor
- Azienda Ospedaliera di Padova
Neuroendocrine Neoplasms
68Ga-NYM215 in NENs
This prospective study will evaluate the safety, biodistribution, dosimetry, and imaging performance of 68Ga-NYM215 PET/CT in patients with neuroendocrine neoplasms.
- Trial name
- NCT07835906
- Testing
- 68Ga-NYM215 PET/CT, 68Ga-DOTATATE PET/CT
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Peking Union Medical College Hospital